By: Michael Furrow , DLA Piper, and Whitney Meier , Venable LLP The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated pathway for companies to bring biologic drugs to market that are biosimilar to previously approved branded...

By: Winston Penhall , Reed Smith LLP This article addresses common questions and concerns regarding the marketing of alternative investment funds in the European Economic Area (EEA), should a “hard Brexit” occur. Hard Brexit is a scenario...